scholarly journals CLINICAL STUDY OF LAGHUPANCHMOOLA SADHIT COW’S MILK IN COW’S MILK PROTEIN ALLERGY

AYUSHDHARA ◽  
2020 ◽  
pp. 2586-2590
Author(s):  
Sujata Sharma ◽  
Avdesh Dangwal ◽  
Reena Pandey ◽  
N. Sujatha

In Ayurveda classics it is pointed out that cow’s milk have Vamaka, Virechaka, Sarama and Abhisyandi properties. In classics, it has been mentioned that cow milk should always be processed with Laghupanchmoola before it is consumed. Aims and Objectives of the study: To study Aetiopathogensis of cow milk protein allergy and to evaluate the efficacy of Laghupanchmoola sadhit cow milk in CMPA. Material & Methods: To fulfill the above Aims and Objectives: Total 35 patients were selected between the age group of 0-3 years of age with symptoms of CMPA. Hb%, complete history and elimination-challenge test were used for evaluation of the patients. Laghupanchmoola granules dose depend upon age and duration of trial was 60 days. Results: After analyzing the data statistically in 30 patients, statistically highly significant improvements were found in diarrhea, abdominal pain, respiratory difficulty and vomiting. Significant improvements were found in dermatitis. No improvement was found in anemia and nausea. Statistically highly significant improvement was found in weight, height, mid arm circumference, chest circumference and head circumference. After full observation of treatment modules, it was found that: Number of patient with complete improvement was 0, Number of patient unchanged was 2 (6.5%), Mild improvement was observed in 05 patients (16.6%), and Moderate improvement was observed in 21 patients (70%), where marked improvement was observed in 2 patients (6.7%). Conclusion: Laghupanchmoola proved quite effective in managing the patients of CMPA due to its Tridoṣahar, Deepana, Aamdoshanasaka, Balya and Brahmanna properties.

Dairy ◽  
2021 ◽  
Vol 2 (2) ◽  
pp. 191-201
Author(s):  
Young W. Park ◽  
George F. W. Haenlein

A new type of cow’s milk, called A2 milk, has appeared in the dairy aisles of supermarkets in recent years. Cows’ milk generally contains two major types of beta-casein as A1 and A2 types, although there are 13 genetic variants of β-casein: A1, A2, A3, A4, B, C, D, E, F, H1, H2, I and G. Studies have shown that A1 β-casein may be harmful, and A2 β-casein is a safer choice for human health especially in infant nutrition and health. The A2 cow milk is reportedly easier to digest and better absorb than A1 or other types of milk. The structure of A2 cow’s milk protein is more comparable to human breast milk, as well as milk from goats, sheep and buffalo. Digestion of A1 type milk produces a peptide called β-casomorphin-7 (BCM-7), which is implicated with adverse gastrointestinal effects on milk consumption. In addition, bovine milk contains predominantly αs1-casein and low levels or even absent in αs2-casein, whereby caprine milk has been recommended as an ideal substitute for patients suffering from allergies against cow milk protein or other food sources. Since goat milk contains relatively low levels of αs1-casein or negligible its content, and αs2-casein levels are high in the milk of most dairy goat breeds, it is logical to assume that children with a high milk sensitivity to αs1-casein should tolerate goat milk well. Cow milk protein allergy (CMPA) is considered a common milk digestive and metabolic disorder or allergic disease with various levels of prevalence from 2.5% in children during the first 3 years of life to 12–30% in infants less than 3 months old, and it can go up to even as high as 20% in some countries. CMPA is an IgE-mediated allergy where the body starts to produce IgE antibodies against certain protein (allergens) such as A1 milk and αs1-casein in bovine milk. Studies have shown that ingestion of β-casein A1 milk can cause ischemic heart disease, type-1 diabetes, arteriosclerosis, sudden infant death syndrome, autism, schizophrenia, etc. The knowledge of bovine A2 milk and caprine αs2-casein has been utilized to rescue CMPA patients and other potential disease problems. This knowledge has been genetically applied to milk production in cows or goats or even whole herds of the two species. This practice has happened in California and Ohio, as well as in New Zealand, where this A2 cow milk has been now advanced commercially. In the USA, there have been even promotions of bulls, whose daughters have been tested homozygous for the A2 β-casein protein.


2021 ◽  
Vol 9 (2) ◽  
pp. 375-389
Author(s):  
Mashail A Baghlaf ◽  
Noura M S Eid

Cow milk protein allergy (CMPA) becoming a major public health issue that has attracted the attention of health professionals and researchers. This paper aimed to review the important aspects of both IgE and IgG types of cow’s milk protein allergy in terms of prevalence, clinical manifestation, risk factors, other health-related issues and nutritional therapy proposed for such allergies in the adult and pediatric population in Saudi Arabia. A search on “cow’s milk allergy” was done using PubMed, Google Scholar and Scopus Engine for published papers between 1993 and 2020 to find studies yielding knowledge on that context. The prevalence of cow’s milk protein allergy (CMPA) among infants is now in the range of 2–3%. This type of allergy is also detected in adulthood but less frequently. CMPA is defined as an immunological reaction to specific proteins in milk. CMPA is classified based on its type as an immunoglobulin E (IgE)-mediated form and an immunoglobulin G (IgG)-mediated form, each type representing different immunological pathways. The presence of Genetic aspects, family history and short duration of breastfeeding in the infant are among the risk factors contributing to this form of allergy. Its manifestations mainly present as skin presentation, followed by the gastrointestinal and respiratory presentation in most cases in addition to a life-threatening anaphylactic reaction that may occur in 12% of cases. food allergy committees have developed strict diagnosis criteria, including blood testing for food-specific immunoglobulin E (sIgE), a skin prick test and double-blind placebo-controlled food challenges (DBPCFC) as the gold standard. A diet free of cow’s milk protein (CMP) allergen and including the appropriate alternative milk formula is the first line of prevention recommended by many organizations and food allergy experts. As for Saudi Arabia, more research and clinical trials are required to discuss the various aspects of adult and pediatric CMPA and to provide a better understanding along with good control strategies implementation.


2020 ◽  
Vol 11 (2) ◽  
Author(s):  
Reni Ilmiasih

Introduction: Regurgitation is a common issue in infants under six months of age who are at risk of esophagitis with excessive frequency and volume. This problem is due, in part, to allergies in the whey protein content in Cow's milk. Objective: The purpose of this research was to examine the connection between Cow's milk consumption and processed products by mothers with regurgitation frequency in infants. Method: This form of study is cross-sectional, with 44 respondents using a purposeful sampling technic in mothers who have children under six months of age. Analysis of data using the Independent t-test test with a nominal scale of data. Result:  The findings showed an average regurgitation frequency was 2.4 times, and the results of the study showed an association between Cow's milk intake and refined goods by mothers with regurgitation in infants under six months with a p-value:0.014. Discussion: Enhanced frequency of regurgitation in mothers who consume Cow's milk and processed foods because of the risk of childhood allergy to the quality of Cow's milk protein, and it is advised that parents be conscious of the frequency of regurgitation due to mother-eaten food.


QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Zeinab A El-Sayed ◽  
Rasha H El-Owaidy ◽  
Hanan M Abd El-Lateef ◽  
Ahmed SA Hammouda

Abstract Background There are insufficient published data on the prevalence of cow's milk protein allergy (CMPA) in Egypt. Aim of the Work The study aims to estimate the frequency of CMPA among young Egyptian children in a trial to delineate the magnitude of the problem in our population. Methods A cross-sectional, observational study was conducted on 500 young Egyptian children from the general population aged from 6 months to 5 years; 200 males and 300 females. Children were subjected to history taking and clinical examination. Suspected cases with suggestive clinical history of CMPA were subjected to skin prick test (SPT) with standardized cow’s milk protein allergen extract and open oral challenge test (OCT). Results In the present study, 6.2% of screened children had positive clinical history suggestive of CMPA, 35.5% of them had positive SPT and 51.6% had positive OCT. Based on clinical history and OCT, 3.2% were documented to have CMPA, 3% had undocumented CMPA or low probability of CMPA and 93.8% had no CMPA. The highest rate of initial onset of CMPA is seen before the first year of life (96.8%) and 81.3% of children with positive OCT were formula/mixed-fed. The clinical manifestations in infants with suspected CMPA were variable, and the main presenting feature was gastrointestinal tract manifestations (42%). The IgE-mediated CMPA was more common and constituted 56.3% of the CMPA cases. Conclusion The frequency of CMPA among Egyptian children up to 5 years of age is comparable to the reported frequencies worldwide. IgE-mediated CMPA accounts for more than 2/3 of the patients with proven CMPA in this study.


Author(s):  
Gennadiy A. Novik ◽  
Maria V. Zhdanova ◽  
Yulia O. Zaitseva ◽  
Anastasiia S. Demidova

Well-recognized tactic for the management of formula-fed children with cow’s milk protein allergy (CMPA) is exclusion of whole cow milk protein and its replacement with extensively hydrolyzed or amino acid formula. One of the most topical issue is the choice of therapeutic formula for a child with CMPA. This article presents information about the clinical manifestations of CMPA and describes the principles of nutrition therapy. All the stages of preparation of adapted therapeutic formula are discussed in detail. It has been shown that the choice of therapeutic formula for a child with CMPA depends on the disease clinical manifestations, their severity, and the presence of comorbid conditions. Current requirements for extensively hydrolyzed formula are reduced to limitations in the size of peptides with immunoreactive properties and indicate the need for evidence of the clinical efficacy of such formula in double-blind placebo-controlled studies.


2012 ◽  
Vol 105 (1-3) ◽  
pp. 202-205 ◽  
Author(s):  
M. Albenzio ◽  
A. Campanozzi ◽  
M. D’Apolito ◽  
A. Santillo ◽  
M. Pettoello Mantovani ◽  
...  

2020 ◽  
pp. 33-37
Author(s):  
A. A. Galimova ◽  
E. E. Emelyashenkov ◽  
S. G. Makarova ◽  
N. N. Murashkin ◽  
A. P. Fisenko ◽  
...  

Relevance. Dairy-free diet is the basis of cow’s milk allergy (CMA) patient’s management. Duration of the diet is individual, but some children don’t develop tolerance.The aim of the study was to investigate health and growth indices in children with CMA depending on tolerance development by the age of five. Materials and methods. 153 children from 1 to 18 months with diagnosed CMA were included in the prospective study (76.5% with IgE-mediated form). The tolerance was determined after 6–12 months of a milk-free diet and at the age of 5 using an open challenge test. Anthropometry indices (Anthro Plus), levels of specific IgE (Immuno CAP 250) and IgG4 (ELISA) to dietary proteins and the presence of allergic diseases in children also were assessed.Results. 50.3% of children developed tolerance to cow’s milk protein after 6–12 months of a milk-free diet. By the age of 5 63.3% of patients had complete tolerance of dairy products. Partially formed tolerance was observed in 22.9%. 13.8% of patients still had clinical reactions to cow’s milk proteins. Patients with persistent CMA typically had IgE-mediated form, lower growth indices and multiple allergic pathology.Conclusion. The consideration of tolerance development predictors can allow to personalize the management of CMA. Additional researches are needed to clarify the causes of growth indices decline in children with persistent CMA. 


2019 ◽  
Vol 25 (3) ◽  
pp. 129-131
Author(s):  
Balasa Adriana ◽  
Mihai Cristina ◽  
Pruna Irina ◽  
Chisnoiu Tatiana ◽  
Daineanu Diana ◽  
...  

Abstract Cow’s milk protein allergy (CMPA) is the most common food allergy found in children under 3 years of age. In most cases, it occurs in infancy. Early diagnosis and appropriate treatment can decrease the risk of impaired growth. In our study, we evaluated 40 children, with ages between 1 month and 3 years, diagnosed with IgE-mediated or non-IgE-mediated CMPA, from january to december 2017, in the Department of Pediatrics of the Clinical Emergency County Hospital of Constanta. The inclusion criteria consisted of: age, natural or artificial feeding, specific IgE levels, CoMiSS score, and clinical manifestations. The Cow’s Milk-related-Symptom-Score (CoMiSS) was developed as a screening and diagnostic tool for CMPA prediction, and can guide pediatricians and primary care physicians to make an early diagnostic, as it can be easily missed. We observed a higher number of cases of CMPA registered among children who were artificially fed (57,5%), followed by those with mixed nutrition (25%), the remaining (17,5%) being represented by exclusively breastfed infants. The most frequent clinical manifestations were rashes (87,5%), failure to thrive (82,5%), regurgitation (50%) and diarrhea (35%). Further data should be collected to prove if the association between a CoMiSS score higher than 12 and specific IgE-mediated CMPA is clinically relevant, and can predict, based on clinical examination and anamnesis, high serum levels of specific immunoglobulin E. The prognosis can depend on the titre of specific IgE at the time of diagnosis, as they are more likely to develop several crossed allergies and less prone to become tolerant to cow milk proteins than those with non-IgE-mediated CMPA.


Sign in / Sign up

Export Citation Format

Share Document